Of clinical relevance, we found that ovarian cancer patients bearing a low level of MIR1305 and high expression of DIRAS3 have a longer overall survival compared to patients in which the CNV of MIR1305 was unaltered. Here, DIRAS3 is linked to ovarian carcinoma.